Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (DE:SNW)
:SNW
Holding DE:SNW?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.47Last Year’s EPS
1.66Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: 0.60%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Positive
The earnings call reflected strong sales performance, driven by key products like Dupixent and successful pharma launches, leading to raised EPS guidance. However, challenges such as product exclusivity losses and regulatory impacts were noted. Overall, the positive aspects significantly outweigh the challenges.Company Guidance
In the Q3 2024 earnings call for Sanofi (SAN.PA), the company reported robust metrics across several business segments. Sanofi recorded a total Q3 sales of EUR 13.4 billion, marking a 16% increase at constant exchange rates (CER), and 11% growth excluding the impact of phasing. The company's standout performance was driven by Dupixent, which achieved near EUR 3.5 billion in sales for the quarter, a 67% increase in sales from new pharma launches, and a 26% growth in the vaccines business. Sanofi's strategic acquisition of Qunol enabled an 8% growth for Opella. They raised their business EPS guidance for 2024, reflecting strong momentum. Looking forward, Sanofi expects continued solid year-on-year growth, planning for Beyfortus sales to reach EUR 1.5 billion for 2024. Overall, Sanofi anticipates a low single-digit increase in business EPS for the full year.Strong Q3 Sales Performance
Total Q3 sales reached EUR 13.4 billion, marking a 16% increase at constant exchange rates, with an estimated 11% excluding the impact of phasing.
Dupixent's Expanding Success
Dupixent sales reached close to EUR 3.5 billion in Q3, driven by global volume growth and new indication approvals, with a sales ambition of around EUR 13 billion for the full year 2024.
Vaccines Business Growth
The vaccines business grew by 26%, supported by flu and Beyfortus sales. Beyfortus showed an exceptional market uptake with EUR 645 million in Q3 sales.
Pharma Launch Success
Pharma launches showed a 67% increase in sales, driven by strong performance across 8 recently launched medicines.
Business EPS Guidance Raised
Sanofi raised its business EPS guidance for 2024, reflecting continued momentum and value delivery to stakeholders.
Opella's Strategic Growth
Opella's 8% growth was driven by the strategic acquisition of Qunol in the U.S., enhancing Sanofi's consumer health care market presence.
---
DE:SNW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:SNW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 25, 2024 | €97.58 | €100.16 | +2.64% |
| Jul 25, 2024 | €93.59 | €97.13 | +3.78% |
| Apr 25, 2024 | €84.31 | €88.23 | +4.65% |
| Feb 01, 2024 | €89.61 | €86.37 | -3.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sanofi (DE:SNW) report earnings?
Sanofi (DE:SNW) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Sanofi (DE:SNW) earnings time?
Sanofi (DE:SNW) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sanofi stock?
The P/E ratio of Sanofi is N/A.
What is DE:SNW EPS forecast?
DE:SNW EPS forecast for the fiscal quarter 2024 (Q4) is 1.47.
---